<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6957294</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0227796</article-id><article-id pub-id-type="publisher-id">PONE-D-19-24367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Antibodies</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pediatrics</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Epilepsy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Pain</subject><subj-group><subject>Abdominal Pain</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Pain</subject><subj-group><subject>Abdominal Pain</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Adverse Events</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children</article-title><alt-title alt-title-type="running-head">Predictors of IVIG-AEs in children</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-1891-4746</contrib-id><name><surname>Kubota</surname><given-names>Jun</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Hamano</surname><given-names>Shin-ichiro</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daida</surname><given-names>Atsuro</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hiwatari</surname><given-names>Erika</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ikemoto</surname><given-names>Satoru</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Yuko</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Matsuura</surname><given-names>Ryuki</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hirano</surname><given-names>Daishi</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Division of Neurology, Saitama Children's Medical Center, Saitama, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department for Child Health and Human Development, Saitama Children's Medical Center, Saitama, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Aktas</surname><given-names>Orhan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Heinrich-Heine-Universitat Dusseldorf, GERMANY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interest exist.</p></fn><corresp id="cor001">* E-mail: <email>junkubota13@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e0227796</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Kubota et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Kubota et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0227796.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Intravenous immunoglobulin (IVIG) therapy is used in the treatment of various diseases, and IVIG-related adverse effects (IVIG-AEs) vary from mild to severe. However, the mechanisms underlying IVIG-AEs and the potential predictive factors are not clear. This study investigated whether certain IVIG-AEs can be predicted before IVIG administration.</p></sec><sec id="sec002"><title>Study design and methods</title><p>This retrospective cohort study at the Division of Neurology, Saitama Children&#x02019;s Medical Center included patients enrolled from 2008 to 2018 who were &#x0003c;&#x02005;18 years old and received IVIG for the first time. IVIG-AEs were classified according to the Common Terminology Criteria for Adverse Events version 5.0.</p></sec><sec id="sec003"><title>Results</title><p>A total of 104 patients fulfilled the inclusion criteria. The rate of IVIG-AEs was 37.5% (39/104). The most frequent IVIG-AEs were fever (41.0% [16/39]) and headache (38.5% [15/39]). AEs were below grade 2 in all except one patient and there were no grade 4 AEs. High serum total protein (TP) level was significantly related to the occurrence of IVIG-AEs (odds ratio, 14.8; 95% confidence interval, 2.4&#x02013;90.5; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01). The optimal cutoff TP level was 6.7 g/dL. Although low WBC count and immunoglobulin G level may be predictive risk factors of IVIG-AEs, it was not confirmed in this study.</p></sec><sec id="sec004"><title>Conclusion</title><p>IVIG-AEs occurred in 37.5% of cases, and most were mild. TP was the best predictive risk factor of IVIG-AEs before IVIG administration. These results may aid in elucidating the mechanism underlying IVIG-AEs.</p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Intravenous immunoglobulin (IVIG) therapy is widely used in the treatment of primary and secondary immunodeficiency diseases, Kawasaki disease, idiopathic thrombocytopenic purpura, and neurological diseases, such as Guillain&#x02013;Barr&#x000e9; syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, polymyositis, multiple sclerosis, autoimmune encephalitis, and epilepsy [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref002" ref-type="bibr">2</xref>]. Regardless of age, disease, and severity of adverse effects (AEs), the incidence of IVIG-related AEs (IVIG-AEs) has been reported to be 0.6% &#x02013;&#x02005;87.5% [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>]. The incidences of IVIG-AEs were reported to be lower in children than in adults; however, they still range from less than 1% to 40% [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref012" ref-type="bibr">12</xref>]. Three major issues arising from prior studies include the large heterogeneity of AE definitions, the relatively small sample sizes, and the large variation in underlying diseases. It is possible that the lower incidence of IVIG-AEs in children results from the fact that children, especially infants, cannot complain of subjective IVIG-AEs such as headache, nausea, and abdominal pain.</p><p>IVIG-AEs are divided into immediate AEs that occur during or within 30 minutes after starting IVIG administration and delayed AEs that occur from 8 hours to 10 days after commencement of IVIG administration [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. In a previous prospective study of IVIG-AEs in pediatric patients, the incidence rates of immediate and delayed AEs were reported to be 10.3% and 41.4%, respectively [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>]. Although delayed AEs were reported to be more common IVIG-AEs in children, this study evaluated only 58 cases, with a small total number of infusions (345 infusions) [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>]. Immediate AEs in adult and pediatric patients show mild flu-like symptoms, such as headache, flushing of the face, malaise, tightness in the chest, fever, chills, myalgia, fatigue, dyspnea, back pain, nausea, and tachycardia [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. In contrast, the symptoms of delayed AEs include severe symptoms, such as acute renal failure, thromboembolic events, neurological toxicity (i.e., aseptic meningitis), hematological toxicity, dermatological toxicity, pseudohyponatremia, arthritis, and pulmonary complications [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. Several previous studies suggested that migraine may be a risk factor for aseptic meningitis associated with IVIG [<xref rid="pone.0227796.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0227796.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0227796.ref016" ref-type="bibr">16</xref>]. Other studies suggested that IVIG infusion rate, primary infusion of IVIG, history of IVIG-AEs, hydration before and after IVIG infusion, immunoglobulin preparation, underlying diseases (immunoglobulin A deficiency, hypertension, thrombopoiesis, etc.), and age may be risk factors of IVIG-AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0227796.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0227796.ref018" ref-type="bibr">18</xref>]. However, clinical data regarding predictive risk factors for IVIG-AEs are limited. The mechanisms underlying IVIG-AEs, including both immediate and delayed AEs, have yet to be elucidated.</p><p>It can be difficult to distinguish between exacerbation of underlying disease and IVIG-AEs, especially in children, because of the similarity of some symptoms, such as headache, vomiting, nausea, and fever. Depending on the symptoms of IVIG-AEs, slowing the IVIG infusion rate or discontinuing IVIG may prolong the treatment period and thus lead to an extended period of hospitalization. The ability to predict patients at high risk of IVIG-AEs prior to administration of IVIG would make it possible to prevent or reduce the incidence of these effects. In addition, identifying predictive factors of IVIG-AEs may provide insight into the underlying mechanisms responsible for these events.</p><p>This study was performed to determine whether it is possible to predict IVIG-AEs in pediatric patients including both immediate and delayed AEs, based on clinical data collected before administration of the first dose of IVIG.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Study design and patients</title><p>This was a retrospective cohort study performed at Saitama Children&#x02019;s Medical Center, Saitama, Japan.</p><p>Patients &#x0003c;&#x02005;18 years old treated with at least one infusion of IVIG during admission to the Division of Neurology, Saitama Children&#x02019;s Medical Center between February 1, 2008, and March 31, 2018, were considered for inclusion in the study. The exclusion criteria were previous IVIG therapy, application of IVIG therapy for infection, no laboratory examination 14 days before commencement of IVIG, prednisolone treatment, and history of methylprednisolone pulse or adrenocorticotropic hormone treatment before IVIG. As previous studies suggested that corticosteroid may be related to the reduction of IVIG-AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>], patients that had received corticosteroids were also excluded from the present study.</p><p>Sex, age, underlying disease, laboratory data (white blood cell (WBC) count, total protein (TP), blood urea nitrogen (BUN), sodium (Na), glucose, immunoglobulin A (IgA), immunoglobulin G (IgG), and immunoglobulin M (IgM)), calculated osmotic pressure (Na&#x02005;&#x000d7;&#x02005;2&#x02005;+&#x02005;glucose/18&#x02005;+&#x02005;BUN/2.8) [<xref rid="pone.0227796.ref019" ref-type="bibr">19</xref>], immunoglobulin preparation, dosage of IVIG (g/kg), duration of IVIG therapy (days), change in infusion rate (0.6 mL/kg/h during the first 30 minutes to 1 hour, and 1.8 mL/kg/h subsequently), and hydration around and/or during IVIG administration were evaluated. When IVIG was discontinued owing to AEs, IVIG dosage was defined as the total dose after administration if IVIG-AEs occurred outside the period of IVIG administration, or including the dose planned for the day if IVIG-AEs occurred during the period of IVIG administration. The duration of IVIG therapy included the day of AE onset.</p><p>Underlying diseases were divided into five categories: epilepsy, central nervous system disease (encephalitis/encephalopathy, cerebellitis, acute disseminated encephalomyelitis, and clinically isolated syndrome), peripheral nervous system disease (including chronic inflammatory demyelinating polyneuropathy, Guillain-Barr&#x000e9; syndrome, Miller&#x02013;Fisher syndrome, and myelitis), myasthenia gravis, and hypogammaglobulinemia.</p><p>Three immunoglobulin preparations were used in this study: Venoglobulin IH 5%, Kenketsu Glovenin-I, and Kenketsu Venilon-I (<xref rid="pone.0227796.t001" ref-type="table">Table 1</xref>).</p><table-wrap id="pone.0227796.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.t001</object-id><label>Table 1</label><caption><title>Immunoglobulin preparations.</title></caption><alternatives><graphic id="pone.0227796.t001g" xlink:href="pone.0227796.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Venoglobulin IH 5%</th><th align="center" rowspan="1" colspan="1">Kenketsu Glovenin-I</th><th align="center" rowspan="1" colspan="1">Kenketsu Venilon-I</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Manufacturer</td><td align="center" rowspan="1" colspan="1">Japan Blood Products Organization</td><td align="center" rowspan="1" colspan="1">Nihon Pharmaceutical Co., Ltd.</td><td align="center" rowspan="1" colspan="1">Teijin Pharma Ltd.</td></tr><tr><td align="center" rowspan="1" colspan="1">Form</td><td align="center" rowspan="1" colspan="1">Liquid</td><td align="center" rowspan="1" colspan="1">Lyophilized. Cohn-Oncley</td><td align="center" rowspan="1" colspan="1">Lyophilized</td></tr><tr><td align="center" rowspan="1" colspan="1">Method of preparation (including viral inactivation)</td><td align="center" rowspan="1" colspan="1">Pasteurization (60&#x000b0;C, 10 h), low-pH incubation, nanofiltration</td><td align="center" rowspan="1" colspan="1">Polyethylene glycol, ion-exchange, nanofiltration</td><td align="center" rowspan="1" colspan="1">Sulfonation, nanofiltration (virus removal membrane 19 nm)</td></tr><tr><td align="center" rowspan="1" colspan="1">Shelf-life/storage requirements</td><td align="center" rowspan="1" colspan="1">24 months/not more than 10&#x000b0;C, do not freeze</td><td align="center" rowspan="1" colspan="1">24 months</td><td align="center" rowspan="1" colspan="1">24 months/storage at room temperature</td></tr><tr><td align="center" rowspan="1" colspan="1">Preparation time</td><td align="center" rowspan="1" colspan="1">Immediately</td><td align="center" rowspan="1" colspan="1">Unknown, must be dissolved</td><td align="center" rowspan="1" colspan="1">Dissolution time 3 minutes (2.8 &#x000b1; 0.5 minutes): 2.5 g product</td></tr><tr><td align="center" rowspan="1" colspan="1">Sugar content</td><td align="center" rowspan="1" colspan="1">D-Sorbitol: 47.4 mg/mL</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.9% (9 mg/mL)</td></tr><tr><td align="center" rowspan="1" colspan="1">Sodium content</td><td align="center" rowspan="1" colspan="1">2.6 mEq/L</td><td align="center" rowspan="1" colspan="1">391.3 mEq/L (9 mg/mL)</td><td align="center" rowspan="1" colspan="1">171 mEq/L</td></tr><tr><td align="center" rowspan="1" colspan="1">Stabilizer</td><td align="center" rowspan="1" colspan="1">D-Sorbitol</td><td align="center" rowspan="1" colspan="1">Glycine, D-mannitol, NaCl</td><td align="center" rowspan="1" colspan="1">Glycine, D-Mannitol</td></tr><tr><td align="center" rowspan="1" colspan="1">Potential for TSE/prion removal</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">&#x0003e; log10<sup>4.3</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">pH</td><td align="center" rowspan="1" colspan="1">3.9&#x02013;4.4</td><td align="center" rowspan="1" colspan="1">6.4&#x02013;7.2</td><td align="center" rowspan="1" colspan="1">6.4&#x02013;7.2</td></tr><tr><td align="center" rowspan="1" colspan="1">Osmolality</td><td align="center" rowspan="1" colspan="1">Approx. 1 (ratio with physiological saline)</td><td align="center" rowspan="1" colspan="1">400&#x02013;523 mOsm/kg</td><td align="center" rowspan="1" colspan="1">Approx. 2 (ratio with physiological saline)</td></tr><tr><td align="center" rowspan="1" colspan="1">Albumin</td><td align="center" rowspan="1" colspan="1">Not detected</td><td align="center" rowspan="1" colspan="1">Not available</td><td align="center" rowspan="1" colspan="1">0.0025% (0.25 mg/mL)</td></tr><tr><td align="center" rowspan="1" colspan="1">IgA content</td><td align="center" rowspan="1" colspan="1">Below detection level</td><td align="center" rowspan="1" colspan="1">27 &#x003bc;g/mL (3 lot mean)</td><td align="center" rowspan="1" colspan="1">5.0 &#x000b1; 1.4 mg/dL</td></tr><tr><td align="center" rowspan="1" colspan="1">IgG</td><td align="center" rowspan="1" colspan="1">99.80%</td><td align="center" rowspan="1" colspan="1">&#x0003e; 99%</td><td align="center" rowspan="1" colspan="1">90&#x02013;110%</td></tr><tr><td align="center" rowspan="1" colspan="1">Latex content in packaging</td><td align="center" rowspan="1" colspan="1">Not used</td><td align="center" rowspan="1" colspan="1">Not used</td><td align="center" rowspan="1" colspan="1">Not used</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>IgA, immunoglobulin A; IgG, immunoglobulin G; TSE, transmissible spongiform encephalopathy.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Outcome measures</title><p>The primary endpoints were the occurrence of AEs from the first day of IVIG administration to 7 days after the end of IVIG administration.</p></sec><sec id="sec009"><title>Definition of adverse effects</title><p>IVIG-AEs were defined as symptoms appearing from the first day of IVIG administration to 7 days after the end of IVIG administration. Immediate AEs were defined as symptoms occurring during infusion, and delayed AEs were defined as symptoms occurring after the infusion has ceased [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>]. The symptoms of IVIG-AEs were classified according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. [<xref rid="pone.0227796.ref020" ref-type="bibr">20</xref>]. Subjective IVIG-AEs such as headache and abdominal pain were evaluated as much as possible by interviewing guardians if patients could not provide any information on subjective IVIG-AEs. Besides, the Face, Legs, Activity, Cry, and Consolability (FLACC) [<xref rid="pone.0227796.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0227796.ref023" ref-type="bibr">23</xref>] or revised FLACC (r-FLACC) Scale [<xref rid="pone.0227796.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0227796.ref025" ref-type="bibr">25</xref>] was used for those patients. The guardians rated patients&#x02019; pain at its highest stage in each category on a scale of 0 to 2, yielding an overall pain score of 0&#x02012;10 [<xref rid="pone.0227796.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0227796.ref025" ref-type="bibr">25</xref>]. Then, FLACC scores 1&#x02013;3, 4&#x02013;6, and 7&#x02013;10 were classified based on the CTCAE of pain categories, such as headache and abdominal pain, into grades 1, 2 and 3, respectively.</p><p>The first day of IVIG administration was defined as day 1. We evaluated AEs every 24 hours until 7 days after the end of IVIG administration. All AEs that occurred during this period were evaluated. When multiple AEs occurred, the first day of AE occurrence was considered the IVIG-AE onset day.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>Continuous variables are expressed as the median and interquartile range, whereas categorical variables are expressed as frequencies. We used the non-parametric Mann&#x02013;Whitney <italic>U</italic> test for comparisons of continuous variables between the two groups, AE and non-AE, and the chi-square or Fisher&#x02019;s exact test, as appropriate, for analysis of categorical data. Multivariate regression analysis was performed using logistic regression analysis for sex, age, and data that showed significant differences in univariate analysis. Forward stepwise regression analysis was performed for sex, age, and data that showed significant differences in univariate analysis. The stepwise procedure was set using a threshold of 0.05 for inclusion. The cutoff point was determined according to the Youden Index [<xref rid="pone.0227796.ref026" ref-type="bibr">26</xref>] based on the receiver operating characteristic (ROC) curve for data that showed significant differences in multivariate regression analysis.</p><p>Statistical analyses were performed using Stata version 15.1 (Stata Corp., College Station, TX). In all analyses, <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.05 was taken to indicate statistical significance.</p><p>This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and with the ethical guidelines for epidemiological studies issued by the Ministry of Health, Labour and Welfare, Japan. This study was approved by the Saitama Children&#x02019;s Medical Center Institutional Review Board (2018-02-008). Informed consent was not deemed necessary because the data were obtained retrospectively from the patient charts.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Baseline patient characteristics and infusion features</title><p>A total of 136 children underwent IVIG during the study period at our institute, and 104 (76.5%) of these children fulfilled the inclusion criteria (<xref ref-type="fig" rid="pone.0227796.g001">Fig 1</xref>). The baseline characteristics of the patients are shown in <xref rid="pone.0227796.t002" ref-type="table">Table 2</xref>. Dataset is available as Supporting information (<xref ref-type="supplementary-material" rid="pone.0227796.s001">S1 Database</xref>). The median age of the study population was 8.5 months (interquartile range [IQR] 6 &#x02013;&#x02005;54.5 months), and 52.9% were male. The most common underlying disease was epilepsy (66.3%). The median total dosage of IVIG was 1.08 g/kg (IQR 0.86 &#x02013;&#x02005;1.25 g/kg) and the median duration of IVIG therapy was 3 days (IQR 3 &#x02013;&#x02005;5 days). The most frequently selected immunoglobulin preparation was Venoglobulin IH 5% (43.3%). The median first and subsequent infusion rates were 0.56 mL/kg/h (IQR 0.51&#x02013;0.60 mL/kg/h) and 1.70 mL/kg/h (IQR 1.52&#x02013;1.79 mL/kg/h), respectively.</p><fig id="pone.0227796.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.g001</object-id><label>Fig 1</label><caption><title>Patients included and excluded from the study.</title><p>IVIG, intravenous immunoglobulin.</p></caption><graphic xlink:href="pone.0227796.g001"/></fig><table-wrap id="pone.0227796.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.t002</object-id><label>Table 2</label><caption><title>Baseline characteristics of patients.</title></caption><alternatives><graphic id="pone.0227796.t002g" xlink:href="pone.0227796.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Total<break/>(n = 104)</th><th align="center" rowspan="1" colspan="1">Adverse effects <break/>(n = 39)</th><th align="center" rowspan="1" colspan="1">Non-adverse effects <break/>(n = 65)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex (male : female)</td><td align="center" rowspan="1" colspan="1">55:49</td><td align="center" rowspan="1" colspan="1">20:19</td><td align="center" rowspan="1" colspan="1">35:30</td></tr><tr><td align="left" rowspan="1" colspan="1">Age [month], median (IQR)</td><td align="center" rowspan="1" colspan="1">8.5<break/>(6&#x02013;54.5)</td><td align="center" rowspan="1" colspan="1">51<break/>(8&#x02013;91)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">7<break/>(6&#x02013;13)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Disease classification</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Epilepsy</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">19<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">50<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Central nervous system disease<xref ref-type="table-fn" rid="t002fn003">&#x02020;</xref></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peripheral nervous system disease<xref ref-type="table-fn" rid="t002fn004">&#x02021;</xref></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">9<xref ref-type="table-fn" rid="t002fn002">**</xref></td><td align="center" rowspan="1" colspan="1">4<xref ref-type="table-fn" rid="t002fn002">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Myasthenia gravis</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypogammaglobulinemia</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Total IVIG [g/kg], median (IQR)</td><td align="center" rowspan="1" colspan="1">1.08<break/>(0.86&#x02013;1.25)</td><td align="center" rowspan="1" colspan="1">1.06<break/>(0.75&#x02013;1.60)</td><td align="center" rowspan="1" colspan="1">1.08<break/>(0.86&#x02013;1.21)</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of IVIG therapy [days], median (IQR)</td><td align="center" rowspan="1" colspan="1">3 (3&#x02013;5)</td><td align="center" rowspan="1" colspan="1">4 (3&#x02013;5)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">3 (3&#x02013;5)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Immunoglobulin preparations</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Venoglobulin IH 5%</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Kenketsu Glovenin-I</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Kenketsu Venilon-I</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">Change of infusion rate (n)</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr><td align="left" rowspan="1" colspan="1">First infusion rate [mL/kg/h], median (IQR)</td><td align="center" rowspan="1" colspan="1">0.56<break/>(0.51&#x02013;0.60)</td><td align="center" rowspan="1" colspan="1">0.55<break/>(0.51&#x02013;0.61)</td><td align="center" rowspan="1" colspan="1">0.57<break/>(0.51&#x02013;0.60)</td></tr><tr><td align="left" rowspan="1" colspan="1">Subsequent infusion rate [mL/kg/h], median (IQR)</td><td align="center" rowspan="1" colspan="1">1.70<break/>(1.52&#x02013;1.79)</td><td align="center" rowspan="1" colspan="1">1.71<break/>(1.52&#x02013;1.83)</td><td align="center" rowspan="1" colspan="1">1.69<break/>(1.53&#x02013;1.79)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydration around and/or during IVIG administration (n)</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">Laboratory data check days [day], median (IQR)</td><td align="center" rowspan="1" colspan="1">1 (0&#x02013;5)</td><td align="center" rowspan="1" colspan="1">1 (0&#x02013;5)</td><td align="center" rowspan="1" colspan="1">1 (0&#x02013;6)</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC [/&#x003bc;L], median (IQR)</td><td align="center" rowspan="1" colspan="1">8200<break/>(6950&#x02013;11150)</td><td align="center" rowspan="1" colspan="1">7400<break/>(6200&#x02013;8800)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">10000<break/>(7500&#x02013;12500)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">TP [g/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">6.4 (5.8&#x02013;6.8)</td><td align="center" rowspan="1" colspan="1">6.8 (6.1&#x02013;7.0)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">6.1 (5.7&#x02013;6.6)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">BUN [mg/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">9 (6&#x02013;12)</td><td align="center" rowspan="1" colspan="1">10 (8&#x02013;13)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">8 (6&#x02013;11)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Na [mmol/L], median (IQR)</td><td align="center" rowspan="1" colspan="1">138<break/>(137&#x02013;140)</td><td align="center" rowspan="1" colspan="1">139<break/>(138&#x02013;141)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">138<break/>(137&#x02013;139)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Glucose [mg/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">94 (87&#x02013;103)</td><td align="center" rowspan="1" colspan="1">94.5 (86&#x02013;103)</td><td align="center" rowspan="1" colspan="1">93 (87&#x02013;103)</td></tr><tr><td align="left" rowspan="1" colspan="1">IgG [mg/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">591.5<break/>(379.5&#x02013;840.5)</td><td align="center" rowspan="1" colspan="1">754<break/>(505&#x02013;912)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">478.5<break/>(361.0&#x02013;703.0)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IgA [mg/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">32 (16&#x02013;74)</td><td align="center" rowspan="1" colspan="1">62 (25&#x02013;101)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">30 (15&#x02013;52)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IgM [mg/dL], median (IQR)</td><td align="center" rowspan="1" colspan="1">62 (45&#x02013;93)</td><td align="center" rowspan="1" colspan="1">71 (45&#x02013;117)</td><td align="center" rowspan="1" colspan="1">60.5 (47.0&#x02013;86.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Calculated osmotic pressure [mOsm/kg H2O], median (IQR)</td><td align="center" rowspan="1" colspan="1">285.1<break/>(282.6&#x02013;288.5)</td><td align="center" rowspan="1" colspan="1">287.8<break/>(283.9&#x02013;290.2)<xref ref-type="table-fn" rid="t002fn001">*</xref></td><td align="center" rowspan="1" colspan="1">284.7<break/>(282.0&#x02013;287.8)<xref ref-type="table-fn" rid="t002fn001">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>* P &#x0003c; 0.01</p></fn><fn id="t002fn002"><p>** P &#x0003c; 0.05</p></fn><fn id="t002fn003"><p>&#x02020;Central nervous system disease total number (number of adverse effects) = encephalitis/encephalopathy 8 (3), cerebellitis 2 (0), acute disseminated encephalomyelitis 1 (1) and clinically isolated syndrome 1 (1)</p></fn><fn id="t002fn004"><p>&#x02021;Peripheral nervous system disease total number (number of adverse effects) = chronic inflammatory demyelinating polyneuropathy 7 (6), Guillain&#x02013;Barr&#x000e9; syndrome 3 (2), Miller&#x02013;Fisher syndrome 1 (0), myelitis 1 (0), and others 1 (0)</p></fn><fn id="t002fn005"><p>BUN, blood urea nitrogen; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IQR, Interquartile range; IVIG, intravenous immunoglobulin; Na, sodium; TP, total protein; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap><p>The median values of laboratory data were as follows: WBC count, 8200/&#x003bc;L; TP, 6.4 g/dL; IgG, 591.5 mg/dL; IgA, 32 mg/dL; and calculated osmolality, 285.1 mOsm/kg H<sub>2</sub>O.</p></sec><sec id="sec013"><title>Adverse effects</title><p>A total of 65 IVIG-AEs occurred in 39 patients (37.5%) during the study period. <xref rid="pone.0227796.t003" ref-type="table">Table 3</xref> shows the types of immediate and delayed AEs. The incidence of delayed AEs (79.5%, 31/39) was higher than that of immediate AEs (30.8%, 12/39). The most common IVIG-AE was fever. Only one of the patients had a grade 3 AE (headache), and there were no cases of a grade 4 AE. The incidence rate of fever in the study population was 41.0% (16/39). The second most common AE was headache, which had a rate of 38.5% (15/39). Maculopapular rash, vomiting, and nausea occurred with incidence rates of 33.3% (13/39), 25.6% (10/39), and 15.4% (6/39), respectively. The least common AE was abdominal pain, which occurred at a rate of 12.8% (5/39). IVIG-AEs occurred a median of 3 days (IQR, 2 &#x02013;&#x02005;4 days) after IVIG administration.</p><table-wrap id="pone.0227796.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.t003</object-id><label>Table 3</label><caption><title>Immediate and delayed adverse effects.</title></caption><alternatives><graphic id="pone.0227796.t003g" xlink:href="pone.0227796.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Immediate</th><th align="center" rowspan="1" colspan="1">Delayed</th><th align="center" rowspan="1" colspan="1">Grade 1</th><th align="center" rowspan="1" colspan="1">Grade 2</th><th align="center" rowspan="1" colspan="1">Grade 3</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Fever</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Headache</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">Maculopapular rash</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Abdominal pain</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Overall</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>AEs, adverse effects.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>Factors associated with the development of adverse effects</title><sec id="sec015"><title>Univariate/multivariate analyses</title><p>The results of the univariate analysis of characteristics between patients with and without AEs are shown in <xref rid="pone.0227796.t002" ref-type="table">Table 2</xref>. There were no statistically significant differences in sex, IVIG dosage, IVIG preparations, changes in infusion rate, hydration around and/or during IVIG administration, glucose, or IgM between the groups. However, the group with AEs showed significant associations with older age, diseases such as epilepsy and peripheral nervous system diseases, longer duration of IVIG therapy, lower WBC count, and higher TP, BUN, Na, IgG, IgA, and calculated osmotic pressure.</p><p>After adjustment for possible confounding factors, post-administration AEs showed significant associations with TP (odds ratio [OR], 14.8112; 95% confidence interval [CI], 2.4244&#x02013;90.4840; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01), WBC count (OR, 0.9995; 95% CI, 0.9993&#x02013;0.9998; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01), and IgG (OR, 0.9943; 95% CI, 0.9902&#x02013;0.9984; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01) (<xref rid="pone.0227796.t004" ref-type="table">Table 4</xref>).</p><table-wrap id="pone.0227796.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.t004</object-id><label>Table 4</label><caption><title>Multivariate regression analysis for predictive risk factors of IVIG-AEs.</title></caption><alternatives><graphic id="pone.0227796.t004g" xlink:href="pone.0227796.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Odds Ratio<break/>(95% Confidence Interval)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">0.9598 (0.2914&#x02013;3.1616)</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Infant (age &#x0003c; 12 months)</td><td align="center" rowspan="1" colspan="1">2.0760 (0.2814&#x02013;15.3135)</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Epilepsy</td><td align="center" rowspan="1" colspan="1">2.6187 (0.4492&#x02013;15.2653)</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC</td><td align="center" rowspan="1" colspan="1">0.9995 (0.9993&#x02013;0.9998)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">TP</td><td align="center" rowspan="1" colspan="1">14.8112 (2.4244&#x02013;90.4840)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">IgG</td><td align="center" rowspan="1" colspan="1">0.9943 (0.9902&#x02013;0.9984)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">IgA</td><td align="center" rowspan="1" colspan="1">1.0146 (0.9926&#x02013;1.0371)</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Calculated osmotic pressure</td><td align="center" rowspan="1" colspan="1">1.0666 (0.9115&#x02013;1.2481)</td><td align="center" rowspan="1" colspan="1">0.42</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>IgA, immunoglobulin A; IgG, immunoglobulin G; IVIG, intravenous immunoglobulin; IVIG-AEs, IVIG-related adverse effects; TP, total protein; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>Forward stepwise regression analysis</title><p>AEs showed significant associations with TP (OR, 15.3185; 95% CI, 2.6720&#x02013;87.8202; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01), WBC count (OR, 0.9995; 95% CI, 0.9993&#x02013;0.9998; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01), and IgG (OR, 0.9963; 95% CI, 0.9929&#x02013;0.9996; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01). These results are consistent with multivariate analysis.</p></sec><sec id="sec017"><title>Optimal cutoff point for dichotomization</title><p>As shown in <xref ref-type="fig" rid="pone.0227796.g002">Fig 2</xref>, the area under the ROC curve for TP was 0.7308. ROC curve analysis indicated that the optimal cutoff point of TP was 6.7 g/dL.</p><fig id="pone.0227796.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227796.g002</object-id><label>Fig 2</label><caption><title>Receiver operating characteristic curve of total protein.</title><p>The area under the ROC curve was 0.7308. ROC, receiver operating characteristic.</p></caption><graphic xlink:href="pone.0227796.g002"/></fig></sec></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>This observational study was performed to investigate the incidence of IVIG-AEs in pediatric patients. In addition, predictive factors for the development of AEs were identified. To our knowledge, this was the largest study investigating IVIG-AEs to date and the first study investigating IVIG-AEs classified according to the CTCAE [<xref rid="pone.0227796.ref020" ref-type="bibr">20</xref>].</p><p>The incidence of IVIG-AEs in this study was 37.5%, and most were mild to moderate AEs (e.g., CTCAE grades 1 and 2) [<xref rid="pone.0227796.ref020" ref-type="bibr">20</xref>]. The incidences of IVIG-AEs in previous follow-up studies of IVIG infusion in pediatric patients ranged from 1% &#x02013;&#x02005;40% [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref012" ref-type="bibr">12</xref>]. The major issues regarding these studies include the large degree of heterogeneity in AE definitions, relatively small sample sizes, and wide variation of underlying diseases. Limiting the underlying diseases to neurological diseases, IVIG-AEs were reported at rates of 13% &#x02013;&#x02005;21.4% in adults [<xref rid="pone.0227796.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0227796.ref011" ref-type="bibr">11</xref>] and 23.5% in children [<xref rid="pone.0227796.ref012" ref-type="bibr">12</xref>]. The present study population included only patients receiving IVIG for the first time, whereas previous studies to evaluate IVIG-AEs included patients that had received IVIG several times. Several previous studies suggested that first-time IVIG therapy is one of the risk factors of IVIG-AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. It is reported that if IVIG-AEs occur with the first application of IVIG therapy, the occurrence of IVIG-AEs would significantly increase in subsequent IVIG therapies [<xref rid="pone.0227796.ref027" ref-type="bibr">27</xref>]. Therefore, further studies are required to determine the relations between the number of applications of IVIG therapy and IVIG-AEs.</p><p>In this study, IVIG-AEs occurred at a median of 3 days (IQR, 2 &#x02013;&#x02005;4 days) after start of IVIG administration, and most were delayed AEs. Singh-Grewal et al. reported that delayed AEs were more common than immediate AEs [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>]. They suggested that the greater incidence of delayed AEs may have been owing to a lack of recognition of delayed AEs in the previous study, resulting in them being overlooked [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>]. In addition, Markvardsen et al. reported that headaches are exacerbated on day 4 after IVIG [<xref rid="pone.0227796.ref018" ref-type="bibr">18</xref>]. Although the authors reported that most cases of delayed AEs have mild symptoms [<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref018" ref-type="bibr">18</xref>], other authors reported more severe symptoms associated with delayed as compared to immediate AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. This lack of recognition may result in delayed AEs being overlooked. Even with greater recognition of delayed AEs, most delayed AEs are likely to have mild symptoms as in the present study. However, it should be noted that there may be severe or even lethal events, such as thrombotic events, neurological disorders, renal impairment, hematological disorders, electrolyte disturbance, and transfusion-related infection, although their incidence rates may be low [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>].</p><p>In this study, high serum TP level showed a significant relation to the occurrence of IVIG-AEs (OR, 14.8112; 95% CI, 2.4244&#x02013;90.4840; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01), which was speculated to result from the hyperviscosity of the blood caused by the IVIG-induced increase in TP level. In fact, headache is known to be one of the symptoms of hyperviscosity syndrome [<xref rid="pone.0227796.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0227796.ref029" ref-type="bibr">29</xref>]. Steinberger et al. prospectively administered IVIG at a dose of 2 g/kg for 2 &#x02013;&#x02005;5 days in cases of Guillain-Barr&#x000e9; syndrome, multiple sclerosis, myasthenia gravis, immune cytopenia, and immunoglobulin deficiency, and examined changes in both serum TP level and viscosity before and after IVIG administration [<xref rid="pone.0227796.ref019" ref-type="bibr">19</xref>]. They reported that TP levels increased significantly at 6 and 24 hours after IVIG infusion, and the viscosity of the blood increased significantly at 24 hours after IVIG infusion (pre-IVIG, 6 hours post-IVIG, 24 hours post-IVIG: TP = 6.32, 7.10, and 8.15 g/dL, respectively; viscosity = 1.78, 1.89, and 1.98 to H<sub>2</sub>O, respectively) [<xref rid="pone.0227796.ref019" ref-type="bibr">19</xref>]. Bentley et al. also reported that plasma viscosity increases further after IVIG administration, especially as the number of IVIG administration days increases [<xref rid="pone.0227796.ref030" ref-type="bibr">30</xref>]. Therefore, higher TP levels before IVIG administration was suggested to be associated with an increase in viscosity of the blood after IVIG administration. The rates of IVIG-AEs were significantly greater in cases where the TP level was 6.7 or higher in the present study. Further prospective studies are required to determine whether this is the optimal TP cutoff point for predicting the occurrence of IVIG-AEs.</p><p>High WBC count and IgG level were significantly negatively correlated with the occurrence of IVIG-AEs in the present study (OR, 0.9995; 95% CI, 0.9993&#x02013;0.9998; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01, OR, 0.9943; 95% CI, 0.9902&#x02013;0.9984; <italic>P</italic>&#x02005;&#x0003c;&#x02005;0.01, respectively). Although low WBC count and IgG level may be predictive risk factors of IVIG-AEs, it was not confirmed in this study. Future studies evaluating WBC count and IgG stratified according to age may explain their relations with IVIG-AEs and provide insights into the underlying mechanisms of IVIG-AEs.</p><p>This study had a number of limitations. First, the study population was small and limited to patients with neurological diseases. Therefore, the results may not be generalizable to other diseases. However, these results may help to distinguish between IVIG-AEs and exacerbation of underlying diseases at the onset of AEs because IVIG therapy is indicated for many neurological diseases. Further studies with a large sample size and addressing various diseases are needed. Second, IVIG-AEs may have been underestimated because of the occurrence of subjective IVIG-AE symptoms such as headache, nausea, and abdominal pain, which were evaluated by the physicians based on interviews with guardians. Therefore, IVIG-AEs may have been underestimated because infants and some patients with epilepsy or mental retardation would not have complained of subjective IVIG-AEs. IVIG-AEs were classified according to the CTCAE [<xref rid="pone.0227796.ref020" ref-type="bibr">20</xref>] in the present study to allow for the use of standardized definitions of IVIG-AEs which makes it possible to compare not only the results in future studies but also to compare AEs between different treatments. Third, only Japanese IVIG preparations were used in this study. However, there were no significant differences in the ingredients of these IVIG preparations compared to those available in other parts of the world [<xref rid="pone.0227796.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0227796.ref032" ref-type="bibr">32</xref>] (<xref rid="pone.0227796.t001" ref-type="table">Table 1</xref>). In addition, the composition of all three immunoglobulin preparations did not change during the study period. Therefore, the results of this study would be generalizable to IVIG preparations available in other countries. Fourth, the infusion rate of IVIG in all patients in this study was less than the maximum of 1.8 mL/kg/h, which was within the range described in the package inserts of Japanese IVIG preparations. Previous studies have shown that a maximum infusion rate for 5% IVIG preparations should be 4 mL/kg/h [<xref rid="pone.0227796.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>]. Although a slower infusion rate is associated with greater reduction in the incidence of IVIG-AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0227796.ref014" ref-type="bibr">14</xref>], no significant association between infusion rate and occurrence of IVIG-AEs was observed in this study. Previous studies reported similar results [<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref018" ref-type="bibr">18</xref>]. Therefore, the relation between infusion rate and the occurrence of IVIG-AEs is still controversial. We could not stratify laboratory data by age because of the small sample size. The final limitation of the present study was that laboratory data were not evaluated after the end of IVIG administration and at the onset of IVIG-AEs. Such evaluations should be included in future studies.</p><p>At present, there is inadequate evidence for the efficacy of pretreatments for IVIG-AEs, and such treatments are controversial. Although pretreatments cannot prevent IVIG-AEs, some treatments, such as hydration, acetaminophen, nonsteroidal anti-inflammatory drugs, antihistamines, and corticosteroids, have been reported to reduce the incidence of IVIG-AEs [<xref rid="pone.0227796.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0227796.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0227796.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0227796.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0227796.ref033" ref-type="bibr">33</xref>]. It is difficult to distinguish between IVIG-AEs and exacerbation of underlying diseases, especially for relatively inexperienced physicians. A number of treatment options have been reported for when IVIG-AEs occur, such as decreasing the infusion rate or discontinuation of IVIG [<xref rid="pone.0227796.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0227796.ref013" ref-type="bibr">13</xref>]; however, the occurrence of IVIG-AEs and reducing or stopping infusions would delay the treatment of underlying diseases. The identification of predictive factors for IVIG-AEs will allow comparative prospective studies in high-risk groups to develop effective pretreatments.</p></sec><sec sec-type="conclusions" id="sec019"><title>Conclusions</title><p>The incidence of IVIG-AEs in first-time IVIG therapy was 37.5%, and most were mild-to-moderate delayed AEs. It is important to recognize the high incidence rate of delayed AEs. The occurrence of IVIG-AEs, especially headache, was strongly associated with TP levels&#x02005;&#x02265;&#x02005;6.7 g/dL, owing to blood hyperviscosity. IVIG therapy is widely used for various diseases. Future studies should examine the validity of TP = 6.7 g/dL as a cutoff point for the prediction of IVIG-AEs. It will also be necessary to further identify the predictive factors and mechanisms underlying the occurrence of IVIG-AEs.</p></sec><sec sec-type="supplementary-material" id="sec020"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0227796.s001"><label>S1 Database</label><caption><p>(XLSX)</p></caption><media xlink:href="pone.0227796.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the Kubota family for their encouragement and helpful advice.</p></ack><ref-list><title>References</title><ref id="pone.0227796.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>Y</given-names></name>, <name><surname>Tian</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Xiao</surname><given-names>Z</given-names></name>. <article-title>Adverse Effects of Immunoglobulin Therapy</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>: <fpage>1299</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2018.01299</pub-id> PubMed Central PMCID: PMC6008653. <?supplied-pmid 29951056?><pub-id pub-id-type="pmid">29951056</pub-id></mixed-citation></ref><ref id="pone.0227796.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Geng</surname><given-names>J</given-names></name>, <name><surname>Dong</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Ni</surname><given-names>H</given-names></name>, <name><surname>Jiang</surname><given-names>K</given-names></name>, <name><surname>Shi</surname><given-names>LL</given-names></name>, <etal>et al</etal>
<article-title>Intravenous immunoglobulins for epilepsy</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2017</year>;<volume>7</volume>: <fpage>CD008557</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD008557.pub3</pub-id> .<?supplied-pmid 28675262?><pub-id pub-id-type="pmid">28675262</pub-id></mixed-citation></ref><ref id="pone.0227796.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Singh-Grewal</surname><given-names>D</given-names></name>, <name><surname>Kemp</surname><given-names>A</given-names></name>, <name><surname>Wong</surname><given-names>M</given-names></name>. <article-title>A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions</article-title>. <source>Arch Dis Child</source>. <year>2006</year>;<volume>91</volume>(<issue>8</issue>):<fpage>651</fpage>&#x02013;<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2005.078733</pub-id>
<?supplied-pmid 16638785?><pub-id pub-id-type="pmid">16638785</pub-id></mixed-citation></ref><ref id="pone.0227796.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Bharath</surname><given-names>V</given-names></name>, <name><surname>Eckert</surname><given-names>K</given-names></name>, <name><surname>Kang</surname><given-names>M</given-names></name>, <name><surname>Chin-Yee</surname><given-names>IH</given-names></name>, <name><surname>Hsia</surname><given-names>CC</given-names></name>. <article-title>Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center</article-title>. <source>Transfusion</source>. <year>2015</year>;<volume>55</volume>(<issue>11</issue>): <fpage>2597</fpage>&#x02013;<lpage>2605</lpage>. <pub-id pub-id-type="doi">10.1111/trf.13200</pub-id> .<?supplied-pmid 26095012?><pub-id pub-id-type="pmid">26095012</pub-id></mixed-citation></ref><ref id="pone.0227796.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Katz</surname><given-names>U</given-names></name>, <name><surname>Achiron</surname><given-names>A</given-names></name>, <name><surname>Sherer</surname><given-names>Y</given-names></name>, <name><surname>Shoenfeld</surname><given-names>Y</given-names></name>. <article-title>Safety of intravenous immunoglobulin (IVIG) therapy</article-title>. <source>Autoimmun Rev</source>. <year>2007</year>;<volume>6</volume>(<issue>4</issue>): <fpage>257</fpage>&#x02013;<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2006.08.011</pub-id> .<?supplied-pmid 17317619?><pub-id pub-id-type="pmid">17317619</pub-id></mixed-citation></ref><ref id="pone.0227796.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Bichuetti-Silva</surname><given-names>DC</given-names></name>, <name><surname>Furlan</surname><given-names>FP</given-names></name>, <name><surname>Nobre</surname><given-names>FA</given-names></name>, <name><surname>Pereira</surname><given-names>CT</given-names></name>, <name><surname>Goncalves</surname><given-names>TR</given-names></name>, <name><surname>Gouveia-Pereira</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions</article-title>. <source>Int Immunopharmacol</source>. <year>2014</year>;<volume>23</volume>(<issue>2</issue>): <fpage>442</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2014.09.015</pub-id> .<?supplied-pmid 25257732?><pub-id pub-id-type="pmid">25257732</pub-id></mixed-citation></ref><ref id="pone.0227796.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Palabrica</surname><given-names>FR</given-names></name>, <name><surname>Kwong</surname><given-names>SL</given-names></name>, <name><surname>Padua</surname><given-names>FR</given-names></name>. <article-title>Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study</article-title>. <source>Asia Pac Allergy</source>. <year>2013</year>;<volume>3</volume>(<issue>4</issue>): <fpage>249</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.5415/apallergy.2013.3.4.249</pub-id>
<?supplied-pmid 24260730?><pub-id pub-id-type="pmid">24260730</pub-id></mixed-citation></ref><ref id="pone.0227796.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Thornby</surname><given-names>KA</given-names></name>, <name><surname>Henneman</surname><given-names>A</given-names></name>, <name><surname>Brown</surname><given-names>DA</given-names></name>. <article-title>Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches</article-title>. <source>Ann Pharmacother</source>. <year>2015</year>;<volume>49</volume>(<issue>6</issue>): <fpage>715</fpage>&#x02013;<lpage>726</lpage>. <pub-id pub-id-type="doi">10.1177/1060028015576362</pub-id> .<?supplied-pmid 25757469?><pub-id pub-id-type="pmid">25757469</pub-id></mixed-citation></ref><ref id="pone.0227796.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Souayah</surname><given-names>N</given-names></name>, <name><surname>Hasan</surname><given-names>A</given-names></name>, <name><surname>Khan</surname><given-names>HM</given-names></name>, <name><surname>Yacoub</surname><given-names>HA</given-names></name>, <name><surname>Jafri</surname><given-names>M</given-names></name>. <article-title>The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders</article-title>. <source>J Clin Neuromuscul Dis</source>. <year>2011</year>;<volume>12</volume>(<issue>Suppl 4</issue>): <fpage>S1</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1097/CND.0b013e3182212589</pub-id> .<?supplied-pmid 22361589?><pub-id pub-id-type="pmid">22361589</pub-id></mixed-citation></ref><ref id="pone.0227796.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Shah</surname><given-names>S.</given-names></name>
<article-title>Pharmacy considerations for the use of IGIV therapy</article-title>. <source>Am J Health Syst Pharm</source>. <year>2005</year>;<volume>62</volume>(<issue>16</issue> Suppl 3): <fpage>S5</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.2146/ajhp050282</pub-id> .<?supplied-pmid 16100386?><pub-id pub-id-type="pmid">16100386</pub-id></mixed-citation></ref><ref id="pone.0227796.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Stangel</surname><given-names>M</given-names></name>, <name><surname>Kiefer</surname><given-names>R</given-names></name>, <name><surname>Pette</surname><given-names>M</given-names></name>, <name><surname>Smolka</surname><given-names>MN</given-names></name>, <name><surname>Marx</surname><given-names>P</given-names></name>, <name><surname>Gold</surname><given-names>R</given-names></name>. <article-title>Side effects of intravenous immunoglobulins in neurological autoimmune disorders&#x02014;a prospective study</article-title>. <source>J Neurol</source>. <year>2003</year>;<volume>250</volume>(<issue>7</issue>): <fpage>818</fpage>&#x02013;<lpage>821</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-003-1085-1</pub-id> .<?supplied-pmid 12883923?><pub-id pub-id-type="pmid">12883923</pub-id></mixed-citation></ref><ref id="pone.0227796.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Nosadini</surname><given-names>M</given-names></name>, <name><surname>Mohammad</surname><given-names>SS</given-names></name>, <name><surname>Suppiej</surname><given-names>A</given-names></name>, <name><surname>Sartori</surname><given-names>S</given-names></name>, <name><surname>Dale</surname><given-names>RC</given-names></name>, <collab>Group IiNS</collab>. <article-title>Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome</article-title>. <source>Dev Med Child Neurol</source>. <year>2016</year>;<volume>58</volume>(<issue>11</issue>): <fpage>1180</fpage>&#x02013;<lpage>1192</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.13159</pub-id> .<?supplied-pmid 27242065?><pub-id pub-id-type="pmid">27242065</pub-id></mixed-citation></ref><ref id="pone.0227796.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Orbach</surname><given-names>H</given-names></name>, <name><surname>Katz</surname><given-names>U</given-names></name>, <name><surname>Sherer</surname><given-names>Y</given-names></name>, <name><surname>Shoenfeld</surname><given-names>Y</given-names></name>. <article-title>Intravenous immunoglobulin: adverse effects and safe administration</article-title>. <source>Clin Rev Allergy Immunol</source>. <year>2005</year>;<volume>29</volume>(<issue>3</issue>): <fpage>173</fpage>&#x02013;<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1385/CRIAI:29:3:173</pub-id> .<?supplied-pmid 16391392?><pub-id pub-id-type="pmid">16391392</pub-id></mixed-citation></ref><ref id="pone.0227796.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Cherin</surname><given-names>P</given-names></name>, <name><surname>Marie</surname><given-names>I</given-names></name>, <name><surname>Michallet</surname><given-names>M</given-names></name>, <name><surname>Pelus</surname><given-names>E</given-names></name>, <name><surname>Dantal</surname><given-names>J</given-names></name>, <name><surname>Crave</surname><given-names>JC</given-names></name>, <etal>et al</etal>
<article-title>Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence</article-title>. <source>Autoimmun Rev</source>. <year>2016</year>;<volume>15</volume>(<issue>1</issue>): <fpage>71</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2015.09.002</pub-id> .<?supplied-pmid 26384525?><pub-id pub-id-type="pmid">26384525</pub-id></mixed-citation></ref><ref id="pone.0227796.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Yelehe-Okouma</surname><given-names>M</given-names></name>, <name><surname>Czmil-Garon</surname><given-names>J</given-names></name>, <name><surname>Pape</surname><given-names>E</given-names></name>, <name><surname>Petitpain</surname><given-names>N</given-names></name>, <name><surname>Gillet</surname><given-names>P</given-names></name>. <article-title>Drug-induced aseptic meningitis: a mini-review</article-title>. <source>Fundam Clin Pharmacol</source>. <year>2018</year>;<volume>32</volume>(<issue>3</issue>): <fpage>252</fpage>&#x02013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1111/fcp.12349</pub-id> .<?supplied-pmid 29364542?><pub-id pub-id-type="pmid">29364542</pub-id></mixed-citation></ref><ref id="pone.0227796.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Sekul</surname><given-names>EA</given-names></name>, <name><surname>Cupler</surname><given-names>EJ</given-names></name>, <name><surname>Dalakas</surname><given-names>MC</given-names></name>. <article-title>Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors</article-title>. <source>Ann Intern Med</source>. <year>1994</year>;<volume>121</volume>(<issue>4</issue>): <fpage>259</fpage>&#x02013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-121-4-199408150-00004</pub-id> .<?supplied-pmid 8037406?><pub-id pub-id-type="pmid">8037406</pub-id></mixed-citation></ref><ref id="pone.0227796.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Graf</surname><given-names>J</given-names></name>, <name><surname>Ingwersen</surname><given-names>J</given-names></name>, <name><surname>Lepka</surname><given-names>K</given-names></name>, <name><surname>Albrecht</surname><given-names>P</given-names></name>, <name><surname>Hartung</surname><given-names>HP</given-names></name>, <name><surname>Ringelstein</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases</article-title>. <source>Acta Neurol Scand</source>. <year>2019</year>;<volume>140</volume>(<issue>4</issue>):<fpage>290</fpage>&#x02013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1111/ane.13144</pub-id> .<?supplied-pmid 31269227?><pub-id pub-id-type="pmid">31269227</pub-id></mixed-citation></ref><ref id="pone.0227796.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Markvardsen</surname><given-names>LH</given-names></name>, <name><surname>Christiansen</surname><given-names>I</given-names></name>, <name><surname>Andersen</surname><given-names>H</given-names></name>, <name><surname>Jakobsen</surname><given-names>J</given-names></name>. <article-title>Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2015</year>;<volume>117</volume>(<issue>6</issue>):<fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1111/bcpt.12428</pub-id> .<?supplied-pmid 26096187?><pub-id pub-id-type="pmid">26096187</pub-id></mixed-citation></ref><ref id="pone.0227796.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Steinberger</surname><given-names>BA</given-names></name>, <name><surname>Ford</surname><given-names>SM</given-names></name>, <name><surname>Coleman</surname><given-names>TA</given-names></name>. <article-title>Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia</article-title>. <source>Am J Hematol</source>. <year>2003</year>;<volume>73</volume>(<issue>2</issue>): <fpage>97</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.10325</pub-id> .<?supplied-pmid 12749010?><pub-id pub-id-type="pmid">12749010</pub-id></mixed-citation></ref><ref id="pone.0227796.ref020"><label>20</label><mixed-citation publication-type="other">US Department of Health and Human Services: National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Available from: <ext-link ext-link-type="uri" xlink:href="https://ctepcancergov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7pdf">https://ctepcancergov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7pdf</ext-link>. 2017.</mixed-citation></ref><ref id="pone.0227796.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Merkel</surname><given-names>SI</given-names></name>, <name><surname>Voepel-Lewis</surname><given-names>T</given-names></name>, <name><surname>Shayevitz</surname><given-names>JR</given-names></name>, <name><surname>Malviya</surname><given-names>S</given-names></name>. <article-title>The FLACC: a behavioral scale for scoring postoperative pain in young children</article-title>. <source>Pediatr Nurs</source>. <year>1997</year>;<volume>23</volume>(<issue>3</issue>):<fpage>293</fpage>&#x02013;<lpage>297</lpage>. .<?supplied-pmid 9220806?><pub-id pub-id-type="pmid">9220806</pub-id></mixed-citation></ref><ref id="pone.0227796.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Crellin</surname><given-names>DJ</given-names></name>, <name><surname>Harrison</surname><given-names>D</given-names></name>, <name><surname>Santamaria</surname><given-names>N</given-names></name>, <name><surname>Babl</surname><given-names>FE</given-names></name>. <article-title>Systematic review of the Face, Legs, Activity, Cry and Consolability scale for assessing pain in infants and children: is it reliable, valid, and feasible for use?</article-title>
<source>Pain</source>. <year>2015</year>;<volume>156</volume>(<issue>11</issue>):<fpage>2132</fpage>&#x02013;<lpage>2151</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000000305</pub-id> .<?supplied-pmid 26207651?><pub-id pub-id-type="pmid">26207651</pub-id></mixed-citation></ref><ref id="pone.0227796.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Matsuishi</surname><given-names>Y</given-names></name>, <name><surname>Hoshino</surname><given-names>H</given-names></name>, <name><surname>Shimojo</surname><given-names>N</given-names></name>, <name><surname>Enomoto</surname><given-names>Y</given-names></name>, <name><surname>Kido</surname><given-names>T</given-names></name>, <name><surname>Hoshino</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Verifying the validity and reliability of the Japanese version of the Face, Legs, Activity, Cry, Consolability (FLACC) Behavioral Scale</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e0194094</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0194094</pub-id>
<?supplied-pmid 29534083?><pub-id pub-id-type="pmid">29534083</pub-id></mixed-citation></ref><ref id="pone.0227796.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Malviya</surname><given-names>S</given-names></name>, <name><surname>Voepel-Lewis</surname><given-names>T</given-names></name>, <name><surname>Burke</surname><given-names>C</given-names></name>, <name><surname>Merkel</surname><given-names>S</given-names></name>, <name><surname>Tait</surname><given-names>AR</given-names></name>. <article-title>The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment</article-title>. <source>Paediatr Anaesth</source>. <year>2006</year>;<volume>16</volume>(<issue>3</issue>):<fpage>258</fpage>&#x02013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9592.2005.01773.x</pub-id> .<?supplied-pmid 16490089?><pub-id pub-id-type="pmid">16490089</pub-id></mixed-citation></ref><ref id="pone.0227796.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>LK</given-names></name>, <name><surname>Rahbek</surname><given-names>O</given-names></name>, <name><surname>Nikolajsen</surname><given-names>L</given-names></name>, <name><surname>Moller-Madsen</surname><given-names>B</given-names></name>. <article-title>The revised FLACC score: Reliability and validation for pain assessment in children with cerebral palsy</article-title>. <source>Scand J Pain</source>. <year>2015</year>;<volume>9</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.sjpain.2015.06.007</pub-id> .<?supplied-pmid 29911640?><pub-id pub-id-type="pmid">29911640</pub-id></mixed-citation></ref><ref id="pone.0227796.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Perkins</surname><given-names>NJ</given-names></name>, <name><surname>Schisterman</surname><given-names>EF</given-names></name>. <article-title>The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve</article-title>. <source>Am J Epidemiol</source>. <year>2006</year>;<volume>163</volume>(<issue>7</issue>): <fpage>670</fpage>&#x02013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwj063</pub-id>
<?supplied-pmid 16410346?><pub-id pub-id-type="pmid">16410346</pub-id></mixed-citation></ref><ref id="pone.0227796.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Sherer</surname><given-names>Y</given-names></name>, <name><surname>Levy</surname><given-names>Y</given-names></name>, <name><surname>Langevitz</surname><given-names>P</given-names></name>, <name><surname>Rauova</surname><given-names>L</given-names></name>, <name><surname>Fabrizzi</surname><given-names>F</given-names></name>, <name><surname>Shoenfeld</surname><given-names>Y</given-names></name>. <article-title>Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases</article-title>. <source>Pharmacology</source>. <year>2001</year>;<volume>62</volume>(<issue>3</issue>): <fpage>133</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1159/000056085</pub-id> .<?supplied-pmid 11287813?><pub-id pub-id-type="pmid">11287813</pub-id></mixed-citation></ref><ref id="pone.0227796.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Kwaan</surname><given-names>HC</given-names></name>. <article-title>Hyperviscosity in plasma cell dyscrasias</article-title>. <source>Clin Hemorheol Microcirc</source>. <year>2013</year>;<volume>55</volume>(<issue>1</issue>): <fpage>75</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.3233/CH-131691</pub-id> .<?supplied-pmid 23455837?><pub-id pub-id-type="pmid">23455837</pub-id></mixed-citation></ref><ref id="pone.0227796.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>MJ</given-names></name>, <name><surname>Bogen</surname><given-names>SA</given-names></name>. <article-title>Evidence-based focused review of management of hyperviscosity syndrome</article-title>. <source>Blood</source>. <year>2012</year>;<volume>119</volume>(<issue>10</issue>): <fpage>2205</fpage>&#x02013;<lpage>2208</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2011-04-347690</pub-id> .<?supplied-pmid 22147890?><pub-id pub-id-type="pmid">22147890</pub-id></mixed-citation></ref><ref id="pone.0227796.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Bentley</surname><given-names>P</given-names></name>, <name><surname>Rosso</surname><given-names>M</given-names></name>, <name><surname>Sadnicka</surname><given-names>A</given-names></name>, <name><surname>Israeli-Korn</surname><given-names>S</given-names></name>, <name><surname>Laffan</surname><given-names>M</given-names></name>, <name><surname>Sharma</surname><given-names>P</given-names></name>. <article-title>Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure</article-title>. <source>J Clin Pharm Ther</source>. <year>2012</year>;<volume>37</volume>(<issue>3</issue>):<fpage>286</fpage>&#x02013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2710.2011.01287.x</pub-id> .<?supplied-pmid 21767284?><pub-id pub-id-type="pmid">21767284</pub-id></mixed-citation></ref><ref id="pone.0227796.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Lemm</surname><given-names>G.</given-names></name>
<article-title>Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>59</volume>(<issue>12</issue> Suppl 6): <fpage>S28</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1212/wnl.59.12_suppl_6.s28</pub-id> .<?supplied-pmid 12499468?><pub-id pub-id-type="pmid">12499468</pub-id></mixed-citation></ref><ref id="pone.0227796.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Saeedian</surname><given-names>M</given-names></name>, <name><surname>Randhawa</surname><given-names>I</given-names></name>. <article-title>Immunoglobulin replacement therapy: a twenty-year review and current update</article-title>. <source>Int Arch Allergy Immunol</source>. <year>2014</year>;<volume>164</volume>(<issue>2</issue>): <fpage>151</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1159/000363445</pub-id> .<?supplied-pmid 25011425?><pub-id pub-id-type="pmid">25011425</pub-id></mixed-citation></ref><ref id="pone.0227796.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Hurelbrink</surname><given-names>CB</given-names></name>, <name><surname>Spies</surname><given-names>JM</given-names></name>, <name><surname>Yiannikas</surname><given-names>C</given-names></name>. <article-title>Significant dermatological side effects of intravenous immunoglobulin</article-title>. <source>J Clin Neurosci</source>. <year>2013</year>;<volume>20</volume>(<issue>8</issue>): <fpage>1114</fpage>&#x02013;<lpage>1116</lpage>. <pub-id pub-id-type="doi">10.1016/j.jocn.2012.10.026</pub-id> .<?supplied-pmid 23659929?><pub-id pub-id-type="pmid">23659929</pub-id></mixed-citation></ref></ref-list></back></article>